Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Share-based Compensation (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Share-based Compensation for 6 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 25.9% to $13.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.7 million through Dec 2025, down 33.61% year-over-year, with the annual reading at $62.4 million for FY2025, 33.69% down from the prior year.
  • Share-based Compensation for Q4 2025 was $13.1 million at Relay Therapeutics, up from $6.0 million in the prior quarter.
  • The five-year high for Share-based Compensation was $27.2 million in Q1 2024, with the low at $600000.0 in Q4 2021.
  • Average Share-based Compensation over 5 years is $15.0 million, with a median of $14.5 million recorded in 2022.
  • The sharpest move saw Share-based Compensation tumbled 95.87% in 2021, then soared 2202.83% in 2022.
  • Over 5 years, Share-based Compensation stood at $600000.0 in 2021, then skyrocketed by 2202.83% to $13.8 million in 2022, then soared by 39.44% to $19.3 million in 2023, then dropped by 8.47% to $17.6 million in 2024, then decreased by 25.9% to $13.1 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $13.1 million, $6.0 million, and $9.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.